Recipients of MLL-AF6 AML Sharp1−/− presented significantly longer survival than those of Sharp1+/+ (median survival; 25 vs 17 days, p < 0.0001) (Fig. 4b). The gene discussed is BHLHE41; the disease is acute myeloid leukemia.